Biocartis Nets $41M in Financing for IVD Development, Launch | GenomeWeb

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis said today that it has raised €30 million ($40.5 million) in a Series E equity financing.

The company plans to use the new capital to validate its Idylla platform and to continue developing a range of assays, most of them oncology-related.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.